PharmaDrug Inc. Announces Plans for First-In-Human Clinical Study with PD-001 in Esophageal Cancer

PharmaDrug Inc. plans to conduct a first-in-human study of its lead candidate, PD-001, an enteric-coated cepharanthine-2HCL, in Australia in H2 2023. PD-001 has the potential as a breakthrough therapy for Esophageal cancer patients. The company will leverage orphan drug designation and first-in-human study data to support planned FDA trials in the U.S., enhancing value for investors through a cost-efficient strategy.

Publish Date: 13-02-2023 Source: PharmaDrug Inc.

Esophageal cancer is the seventh leading cause of death in males in the United States (US). Squamous cell carcinoma is the most common histology for EC worldwide; however, adenocarcinoma is the most predominant histology in the US. Early-stage EC may be totally asymptomatic or may present with mild nonspecific symptoms such as heartburn, atypical chest pain, or dyspepsia. Alternatively, patients may present with symptoms such as occult blood in the stool or iron deficiency anemia. Patients may report mild or intermittent dysphagia, odynophagia, or a foreign body sensation. These symptoms generally warrant diagnostic evaluation, including an esophagogastroduodenoscopy (EGD) (upper endoscopy), including a diagnostic mucosal biopsy. Some early cancers are diagnosed during routine upper endoscopic surveillance of Barrett’s esophagus. The symptoms of EC generally progress rapidly.

The overall incidence of esophageal cancer (EC) ranges between 4.7 to 5.8 per 100,000 people per year. Males had a higher incidence of EC than females.

However, the current Esophageal cancer (EC) treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (Nivolumab, CLS2702C, Icotinib, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Esophageal cancer (EC) treatment. The key companies in the advanced development stage are Ono Pharmaceutical Co. Ltd, CellSeed Inc., Betta Pharmaceuticals Co., Ltd, etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Esophageal Cancer to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.